Pazopanib plus cetuximab in recurrent or metastatic head and neck squamous cell carcinoma: an open-label, phase 1b and expansion study

BACKGROUND: Angiogenesis is a hallmark of head and neck squamous cell carcinoma (HNSCC), and a mechanism of resistance to EGFR inhibition. We investigated the safety and potential activity of pazopanib, an angiogenesis inhibitor, plus cetuximab, an EGFR inhibitor, in patients with recurrent or metas...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Lancet Oncol
Autors principals: Adkins, Douglas, Mehan, Paul, Ley, Jessica, Siegel, Marilyn J, Siegel, Barry A, Dehdashti, Farrokh, Jiang, Xuntian, Salama, Noha N, Trinkaus, Kathryn, Oppelt, Peter
Format: Artigo
Idioma:Inglês
Publicat: 2018
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6561471/
https://ncbi.nlm.nih.gov/pubmed/30001987
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(18)30350-4
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars